MX2015013181A - Anticuerpos humanos pac1. - Google Patents
Anticuerpos humanos pac1.Info
- Publication number
- MX2015013181A MX2015013181A MX2015013181A MX2015013181A MX2015013181A MX 2015013181 A MX2015013181 A MX 2015013181A MX 2015013181 A MX2015013181 A MX 2015013181A MX 2015013181 A MX2015013181 A MX 2015013181A MX 2015013181 A MX2015013181 A MX 2015013181A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen
- pac1
- binding fragments
- human pac1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se proporcionan anticuerpos y fragmentos de unión a antígeno de los mismos que se unen a PAC1 humano. También se proporcionan ácidos nucleicos que codifican los anticuerpos y fragmentos de unión a antígeno de los mismos, vectores y células que codifican la misma. Los anticuerpos y fragmentos de unión a antígeno de los mismos pueden inhibir la unión de PAC1 a PACAP, y son útiles en una serie de trastornos relacionados con PAC1, incluyendo el tratamiento y/o prevención de trastornos de dolor de cabeza, incluyendo migraña y la cefalea en racimos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792678P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/029128 WO2014144632A2 (en) | 2013-03-15 | 2014-03-14 | Human pac1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015013181A true MX2015013181A (es) | 2015-12-11 |
Family
ID=50439531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013181A MX2015013181A (es) | 2013-03-15 | 2014-03-14 | Anticuerpos humanos pac1. |
Country Status (24)
Country | Link |
---|---|
US (7) | US9676851B2 (es) |
EP (2) | EP2970470B1 (es) |
JP (3) | JP6283408B2 (es) |
KR (1) | KR102215405B1 (es) |
CN (1) | CN105143267B (es) |
AP (1) | AP2015008732A0 (es) |
AR (1) | AR095611A1 (es) |
AU (2) | AU2014228924B2 (es) |
CA (1) | CA2906737C (es) |
CL (1) | CL2015002750A1 (es) |
CR (1) | CR20150575A (es) |
EA (1) | EA032830B1 (es) |
ES (1) | ES2770976T3 (es) |
HK (2) | HK1218554A1 (es) |
IL (2) | IL241382A0 (es) |
MA (1) | MA38478A1 (es) |
MX (1) | MX2015013181A (es) |
PE (1) | PE20151923A1 (es) |
PH (1) | PH12015502126A1 (es) |
SG (1) | SG11201507416WA (es) |
TN (1) | TN2015000425A1 (es) |
TW (2) | TW201902931A (es) |
UY (1) | UY35483A (es) |
WO (1) | WO2014144632A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016044224A1 (en) | 2014-09-15 | 2016-03-24 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
EP3283169A4 (en) | 2015-04-16 | 2019-03-20 | Alder Biopharmaceuticals, Inc. | USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF FOR THE TREATMENT, PREVENTION OR INHIBITION OF PHOTOPHOBY |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
EA039859B1 (ru) * | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
CN109311977B (zh) | 2016-04-15 | 2022-06-14 | H.伦德贝克公司 | 人源化的抗pacap抗体及其用途 |
AR113022A1 (es) * | 2017-09-29 | 2020-01-15 | Lilly Co Eli | Anticuerpo anti-pacap |
CN111164101A (zh) * | 2017-10-04 | 2020-05-15 | 安进公司 | 甲状腺素视黄质运载蛋白免疫球蛋白融合体 |
US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
BR112020013621A2 (pt) | 2018-01-12 | 2020-12-01 | Amgen Inc. | anticorpos contra pac1 e usos dos mesmos |
EA202092335A1 (ru) | 2018-04-02 | 2021-01-22 | Эмджен Инк. | Композиции на основе эренумаба и пути их применения |
CA3096374A1 (en) | 2018-04-12 | 2019-10-17 | Amgen Inc. | Methods for making stable protein compositions |
EP3990493A1 (en) | 2019-06-28 | 2022-05-04 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
WO2023015298A1 (en) * | 2021-08-06 | 2023-02-09 | Amgen Inc. | Isolation of therapeutic protein |
CN117916259A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 特异性结合cgrp和pacap的抗原结合分子及其医药用途 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
WO1991014786A1 (en) | 1990-03-17 | 1991-10-03 | Takeda Chemical Industries, Ltd. | Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
CA2105984C (en) | 1991-03-11 | 2002-11-26 | Milton J. Cormier | Cloning and expression of renilla luciferase |
AU2249592A (en) | 1991-06-14 | 1993-01-12 | Dnx Corporation | Production of human hemoglobin in transgenic pigs |
EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
WO1994010308A1 (en) | 1992-10-23 | 1994-05-11 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
EP0618291A3 (en) | 1993-02-26 | 1997-12-03 | Takeda Chemical Industries, Ltd. | PACAP receptor protein, method for preparing said protein, and use thereof |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US6146826A (en) | 1993-09-10 | 2000-11-14 | The Trustees Of Columbia University In The City Of New York | Green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US6399316B1 (en) | 1994-02-25 | 2002-06-04 | Takeda Chemical Industries, Ltd. | PACAP receptor protein, method for preparing said protein, and use thereof |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
US6462016B1 (en) | 1995-10-06 | 2002-10-08 | Shiseido Company, Ltd. | Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US6017533A (en) | 1996-04-25 | 2000-01-25 | Shiseido Company, Ltd. | Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
AU741076B2 (en) | 1996-12-12 | 2001-11-22 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
DE69938293T2 (de) | 1998-03-27 | 2009-03-12 | Bruce J. Beverly Hills Bryan | Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose |
ES2335827T3 (es) | 1998-07-20 | 2010-04-05 | Ipsen Pharma | Analogos peptidos de pacap. |
US6242563B1 (en) | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US20020155533A1 (en) | 1998-11-30 | 2002-10-24 | Takeda Chemical | PACAP receptor protein, method for preparing said protein, and use thereof |
US20020182729A1 (en) | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
WO2004046330A2 (en) * | 2002-11-15 | 2004-06-03 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
EP1583550A2 (en) | 2003-01-16 | 2005-10-12 | D. Collen Research Foundation vzw | Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
US20050129687A1 (en) | 2003-11-03 | 2005-06-16 | University Of Vermont And State Agricultural College | Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome |
JP2007522118A (ja) | 2004-01-30 | 2007-08-09 | ペプリン バイオリピッズ ピーティーワイ エルティーディー | 治療用分子および担体分子 |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
CA2620364A1 (en) | 2005-08-26 | 2007-03-01 | David C. Yeomans | Methods for treatment of headaches by administration of oxytocin |
WO2008018472A1 (fr) * | 2006-08-08 | 2008-02-14 | Kyoto University | Nouvel anticorps monoclonal et son utilisation |
WO2009003489A1 (en) | 2007-07-02 | 2009-01-08 | Natimmune A/S | CaOU-1 EPITOPE BINDING POLYPEPTIDES |
WO2009033489A2 (en) | 2007-09-11 | 2009-03-19 | Glostrup Hospital | Selective pacl inhibitors for use in the treatment of migraine and headaches |
CN101434649B (zh) | 2008-12-12 | 2012-04-25 | 余榕捷 | 一种环七肽及其制备方法和应用 |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
NZ597763A (en) | 2009-07-27 | 2014-07-25 | Nocicepta Llc | Methods for treatment of pain |
WO2011035456A1 (zh) * | 2009-09-25 | 2011-03-31 | 上海抗体药物国家工程研究中心有限公司 | 通过计算机辅助设计来获得高亲和力的蛋白质的方法 |
KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질 |
WO2011118739A1 (ja) * | 2010-03-26 | 2011-09-29 | 協和発酵キリン株式会社 | 新規修飾部位導入抗体および抗体フラグメント |
JP5972915B2 (ja) * | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Fc変異体 |
CN102936303A (zh) * | 2011-08-15 | 2013-02-20 | 沈阳欧陆科技发展有限公司 | 一种高氯含量的氯化聚氯乙烯树脂的合成方法 |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
MY181743A (en) | 2012-05-21 | 2021-01-06 | Genentech Inc | Methods for improving safety of blood-brain barrier transport |
WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2014
- 2014-03-14 WO PCT/US2014/029128 patent/WO2014144632A2/en active Application Filing
- 2014-03-14 KR KR1020157028947A patent/KR102215405B1/ko active IP Right Grant
- 2014-03-14 EP EP14715526.1A patent/EP2970470B1/en active Active
- 2014-03-14 EA EA201591791A patent/EA032830B1/ru not_active IP Right Cessation
- 2014-03-14 PE PE2015002006A patent/PE20151923A1/es unknown
- 2014-03-14 SG SG11201507416WA patent/SG11201507416WA/en unknown
- 2014-03-14 US US14/775,995 patent/US9676851B2/en active Active
- 2014-03-14 MX MX2015013181A patent/MX2015013181A/es unknown
- 2014-03-14 ES ES14715526T patent/ES2770976T3/es active Active
- 2014-03-14 CN CN201480021555.2A patent/CN105143267B/zh active Active
- 2014-03-14 EP EP19211989.9A patent/EP3683237A1/en not_active Withdrawn
- 2014-03-14 TW TW107121016A patent/TW201902931A/zh unknown
- 2014-03-14 MA MA38478A patent/MA38478A1/fr unknown
- 2014-03-14 TW TW103109837A patent/TWI636064B/zh not_active IP Right Cessation
- 2014-03-14 CA CA2906737A patent/CA2906737C/en active Active
- 2014-03-14 JP JP2016502989A patent/JP6283408B2/ja active Active
- 2014-03-14 AU AU2014228924A patent/AU2014228924B2/en active Active
- 2014-03-14 AP AP2015008732A patent/AP2015008732A0/xx unknown
- 2014-03-17 AR ARP140101236A patent/AR095611A1/es unknown
- 2014-03-17 UY UY35483A patent/UY35483A/es not_active Application Discontinuation
- 2014-06-13 US US14/304,559 patent/US9365653B2/en active Active
-
2015
- 2015-09-09 IL IL241382A patent/IL241382A0/en unknown
- 2015-09-15 CL CL2015002750A patent/CL2015002750A1/es unknown
- 2015-09-15 PH PH12015502126A patent/PH12015502126A1/en unknown
- 2015-09-15 TN TN2015000425A patent/TN2015000425A1/en unknown
- 2015-10-15 CR CR20150575A patent/CR20150575A/es unknown
-
2016
- 2016-05-18 US US15/158,178 patent/US9822178B2/en active Active
- 2016-06-08 HK HK16106566.3A patent/HK1218554A1/zh unknown
- 2016-07-08 HK HK16108001.2A patent/HK1219958A1/zh unknown
-
2017
- 2017-05-10 US US15/592,115 patent/US10053507B2/en active Active
- 2017-10-18 US US15/787,635 patent/US10294298B2/en active Active
-
2018
- 2018-01-26 JP JP2018011408A patent/JP6443870B2/ja active Active
- 2018-06-25 US US16/017,891 patent/US10472417B2/en active Active
- 2018-11-06 IL IL262804A patent/IL262804A/en unknown
- 2018-11-20 JP JP2018217355A patent/JP2019024501A/ja active Pending
-
2019
- 2019-07-11 AU AU2019204980A patent/AU2019204980A1/en not_active Abandoned
- 2019-09-16 US US16/572,271 patent/US10793631B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502126A1 (en) | Human pac1 antibodies | |
PH12016502505A1 (en) | Bispecific t cell activating antigen binding molecules | |
PH12018500634A1 (en) | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules | |
NZ739252A (en) | Monoclonal antibodies against bcma | |
MY184889A (en) | T cell activating bispecific antigen binding molecules | |
MX2020002694A (es) | Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas. | |
MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
MX2018006385A (es) | Moleculas de anticuerpo contra april y usos de las mismas. | |
WO2017015622A8 (en) | Gdf11 binding proteins and uses thereof | |
PH12015501340A1 (en) | Bispecific t cell activating antigen binding molecules | |
MX2015010843A (es) | Moleculas biespecificas de union al antigeno que activan celulas t. | |
MX2015010350A (es) | Moleculas de union a antigeno biespecificas que activan la celula t. | |
PH12017502207A1 (en) | Tau-binding antibodies | |
NZ702457A (en) | Anti-fcrn antibodies | |
MX2017003247A (es) | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. | |
PH12016500275A1 (en) | Antibodies | |
PH12016500753B1 (en) | Antibodies specific to fcrn |